奥氮平与利培酮治疗精神分裂症阴性症状的对照研究  

Control Study of Olanzapine and Risperidone on Negative Symptoms of Schizophrenia

作　　者：王领军[1] 吴焕[2] 杨福收[1] 

机构地区：[1]河南省精神病医院,河南新乡453002 [2]新乡医学院管理学院

出　　处：《中国药师》2009年第9期1279-1281,共3页China Pharmacist

摘　　要：目的:探讨奥氮平与利培酮对精神分裂症阴性症状的疗效和安全性。方法:分别使用奥氮平与利培酮对86例以阴性症状为主精神分裂症患者治疗12周,用阳性与阴性症状量表(PANSS)、不良反应量表(TESS)评定疗效和安全性。结果:12周末两组PANSS总分及各因子分与治疗前比较有统计学差异(P<0.05或P<0.01)。8、12周末两组间比较PANSS总分及阴性因子分有统计学差异(P<0.05或P<0.01),TESS评分有统计学差异(P>0.05)。结论:奥氮平治疗精神分裂症阴性症状疗效较好,且安全性高。Objective： To study the efficacy and safety of Olanzapine on negative symptoms of schizophrenia. Method： Eighty-six cases of schizophrenics with prominent negative symptoms were randomly divided into study group（ n =43 ） and control group（ n =43） . Forty-three cases of olanzapine treated patients were compared with 43 cases of risperidone treated patients. The duration of study was 12 weeks . The therapeutic efficacy and safety were assessed with the PANSS and TESS respectively. Result： After treatment ,the total scores of PANSS and TESS were statistical differences between two groups （ P 〈 0.05 or P 〈 0.01 ） respectively, especially the total scores of PANSS were significantly differences after 8 or 12 weeks of study between two groups （P 〈 0.05 or P 〈 0. 01 ） ,but the total scores of TESS had no statistical differences （ P 〉 0.05 ）. Conclusion： Olanzapine has an excellent clinical efficacy and safety in the treatment of schizophrenics with prominent negative symptoms.

关 键 词：奥氮平 利培酮 精神分裂症 阴性症状 

分 类 号：R971.41[医药卫生—药品]